[Targeted treatment of cancers with imatinib mesylate (STI571, Gleevec): results of Asco 2002]

Bull Cancer. 2002 Jun;89(6):567-9.

[Article in French]

Authors

Isabelle Ray-Coquard¹, Jean-Yves Blay

Affiliation

¹ Inserm U. 453, Centre Léon-Bérard, 28, rue Laennec, 69008 Lyon, France.

PMID: 12135855

No abstract available

Publication types

Congress

MeSH terms

Antineoplastic Agents / therapeutic use*
Benzamides
Dermatofibrosarcoma / drug therapy
Florida
Gastrointestinal Neoplasms / drug therapy
Gastrointestinal Neoplasms / genetics
Humans
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
Neoplasms / drug therapy*
Neoplasms / genetics
Piperazines / therapeutic use*
Protein-Tyrosine Kinases / therapeutic use*
Proto-Oncogene Proteins c-kit / metabolism
Pyrimidines / therapeutic use*
Sarcoma / drug therapy
Sarcoma / genetics
Skin Neoplasms / drug therapy

Substances

Antineoplastic Agents
Benzamides
Piperazines
Pyrimidines
Imatinib Mesylate
Protein-Tyrosine Kinases
Proto-Oncogene Proteins c-kit